Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Cvmd

blog.png
September 14, 2017 First Type 2 Diabetes Publication Comparing Pros and Cons of Two Preclinical Continuous Glucose Monitoring Systems Significant Correlation between Blood Glucose Levels Measured by Glucometer and both the Dexcom G4 Platinum and HD-XG Telemetry Device from Wang et al. Sci Rep 2017;7(1):9596. LEARN MORE
August 31, 2017 Recent Type 2 Diabetes Publication Demonstrates Preclinical Study Benefits of Continuous Glucose Monitoring Daily Blood Glucose Fluctuations in Normal and Diabetic NHPs from Wang et al. J Endocrinol Invest 2017;40(9): 967-977. ... LEARN MORE
August 17, 2017 How to Optimize your Non GLP Toxicology Studies Most new drug candidates fail in the clinic because they are not efficacious or are not safe. Optimizing non-clinical ... LEARN MORE
August 1, 2017 NASH Drug Development Race Intensifies There is no FDA-approved treatment for NASH, which affects 3-5% of Americans. Competition to deliver the first ... LEARN MORE
July 27, 2017 Polycystic Kidney Disease (PKD): The Argument for Multiple Rodent Models Rodent models of PKD are critical to studying both its molecular basis and progression, but the complexity of ... LEARN MORE
July 13, 2017 Progress Towards a Cure for Polycystic Kidney Disease Polycystic kidney disease (polycystic kidney syndrome, PKD, or PCKD) is a genetic disorder in which numerous abdominal ... LEARN MORE
June 15, 2017 Why the Current Excitement over Krill in CVD? Krill are small crustaceans found in all the world's oceans, which have been harvested as a human and animal food source for many years, recently for use in dietary supplements. A new collaborative study has demonstrated that a novel long-chain (LC) omega-3 rich phospholipid preparation extracted from krill oil can reduce cardiovascular disease risk. LEARN MORE
June 6, 2017 PCSK9 Inhibitor Data in Diabetic Patients to be Highlighted at ADA 2017 Recent years have witnessed a change in cholesterol-lowering compounds - from your parents’ standard statin treatment ... LEARN MORE
May 18, 2017 Can We Develop Translational Platforms that Model Multiple Aspects of Human Diabetes? A significant challenge in the development of new anti-diabetic therapies is the lack of translational platforms that ... LEARN MORE
December 13, 2016 Targeting Cardio-Metabolic Disease Symposium Highlights from the NASH symposium and panel discussion in Boston, MA (Sep 20-21, 2016) Amar Thyagarajan, PhD LEARN MORE
September 27, 2016 All You Need to Know About Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty liver disease (NAFLD) is a complex condition where an excessive amount of fat accumulates in the liver, independently from alcohol consumption. It is currently unclear how and why NAFLD develops, although obesity is a clear risk factor. Improved preclinical models are currently needed so that we can gain a better understanding about the ... LEARN MORE
September 13, 2016 Obesity Linked To Self-Eating Beige Fat Humans, like all mammals, have two types of fat with completely opposite functions: white, which stores energy and when ... LEARN MORE
July 15, 2016 Warming up the Issue of Heat Loss Obesity was classified as a disease by the American Medical Association in 2013, and has become a serious epidemic ... LEARN MORE
March 8, 2016 Novo Nordisk Leads the Way to Cardiovascular Safety in Diabetes Treatment Diabetes is one of the largest global health emergencies of the 21st century. Every year an increasing number of people ... LEARN MORE
December 1, 2015 Fatty Liver Disease And The Need for New Translational Models Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in developed countries, occurring when fat ... LEARN MORE